Maryland Oncology Hematology
Silver Spring, Maryland, United States
Oncologist in Calverton, Maryland
11886 Healing Wy Suite 701, Silver Spring, MD 20904
About Maryland Oncology Hematology
"Today, Maryland Oncology Hematology is the largest independent Medical Oncology and Hematology group in Maryland with 30 physicians practicing in 9 locations across central Maryland. Dedicated to providing the most advanced cancer care available anywhere in an atmosphere of caring compassion."
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Ipsen
2
Apollomics Inc.
1
Daiichi Sankyo, Inc.
1
Gilead Sciences
1
Innocrin Pharmaceutical
1
MediMergent, LLC
1
Pfizer
1
Pieris Pharmaceuticals, Inc.
1
Tizona Therapeutics, Inc
1
Vincerx Pharma, Inc.
1
Clinical Trials at Maryland Oncology Hematology
During the past decade, Maryland Oncology Hematology conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 3 clinical trials were completed, i.e. on
average, 27.3% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 2 clinical trials were completed. i.e. 40%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
2015-10-19
2021-02-15
Completed
56
Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)
2017-11-07
2020-12-08
Completed
529
CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)
2015-08-01
2019-01-01
Completed
175
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
2016-02-10
2024-12-30
Recruiting
110
Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)
2016-05-19
2019-05-16
Terminated
998
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
2017-09-27
2026-11-30
Recruiting
344
A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
2020-02-19
2023-12-31
Active, not recruiting
770
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
2020-07-14
2024-06-01
Recruiting
240
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Maryland Oncology Hematology" #1 sponsor was "Ipsen" with 2 trials, followed by "Apollomics Inc." with 1 trials
sponsored, "Daiichi Sankyo, Inc." with 1 trials sponsored, "Gilead Sciences" with 1 trials sponsored and "Innocrin Pharmaceutical"
with 1 trials sponsored. Other sponsors include 0 different institutions and
companies that sponsored additional 10 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Maryland Oncology Hematology"
#1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "German Breast Group" with 1 trials as a collaborator, "NSABP Foundation Inc" with 1 trials as a collaborator and "Spanish Breast Cancer Research Group (SOLTI)" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were
collaborators in the rest 4 trials.
Clinical Trials Conditions at Maryland Oncology Hematology
According to Clinical.Site data, the most researched conditions in "Maryland Oncology Hematology" are
"Breast Cancer" (2 trials), "Advanced Breast Cancer" (1 trials), "Advanced Cancer" (1 trials), "Brain Tumor" (1 trials) and "Cancer" (1 trials). Many other conditions were trialed in "Maryland Oncology Hematology" in a lesser frequency.
Clinical Trials Intervention Types at Maryland Oncology Hematology
Most popular intervention types in "Maryland Oncology Hematology" are "Drug" (11 trials). Other intervention types were less common.
The name of intervention was led by "Gemcitabine" (2 trials), "Leucovorin" (2 trials), "Oxaliplatin" (2 trials), "5 fluorouracil" (1 trials) and "5Fluorouracil" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Maryland Oncology Hematology
The vast majority of trials in "Maryland Oncology Hematology" are
10 trials for "All" genders and 1 trials for "Female" genders.
Clinical Trials Status at Maryland Oncology Hematology
Currently, there are NaN active trials in "Maryland Oncology Hematology".
undefined are not yet recruiting,
5 are recruiting,
2 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 3 completed trials in Maryland Oncology Hematology,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Maryland Oncology Hematology, 4 "Phase 1"
clinical trials were conducted, 4 "Phase 2" clinical
trials and 5 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".